CD47 as a promising therapeutic target in oncology

Zhao, Hai; Song, Shuangshuang; Ma, Junwei; Zhang, Yan; Xie, Huaqing; Ye, Feng; Che, Shuseng

doi:10.3389/fimmu.2022.757480

Cited by 28 publications

(27 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent evidence has implicated CD47 as a novel innate checkpoint receptor target for cancer immunotherapy. [ 36 ] CD47 plays a pivotal role in tissue homeostasis by delivering a “don't eat me” anti‐phagocytic signals upon binding to the signal‐regulatory protein alpha (SIRP α ) receptor on myeloid cells, such as macrophages, to exert inhibitory effects directly and indirectly on T cells. [ 37 ] The important role of Tnfrsf14 and CD47 in immune homeostasis suggests that the IFN‐ γ ‐induced FLS reg may also inhibit T cells via these pathways; more importantly, the FLS reg cell membrane may crosstalk with various other immune cells at the inflammatory site of RA in addition to T cells, which remains to be further studied.…”

Section: Discussionmentioning

confidence: 99%

Regulatory Fibroblast‐Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

Fibroblast-like synoviocytes (FLS) are the main cell component in the inflamed joints of patients with rheumatoid arthritis (RA). FLS intimately interact with infiltrating T cells. Fibroblasts have potent inhibitory effects on T cells, leading to the resolution of inflammation and immune tolerance. However, this "regulatory" phenotype is defect in RA, and FLS in RA instead act as "proinflammatory" phenotype mediating inflammation perpetuation. Signals that orchestrate fibroblast heterogeneity remain unclear. Here, it is demonstrated that different cytokines can induce distinct phenotypes of FLS. Interferon-gamma (IFN-𝜸) is pivotal in inducing the regulatory phenotype of FLS (which is termed FLS reg ) characterized by high expressions of several inhibitory molecules. Rapamycin enhances the effect of IFN-𝜸 on FLS. Based on the characteristics of FLS reg , a novel biomimetic therapeutic strategy for RA is designed by coating cell membrane derived from FLS reg induced by IFN-𝜸 and rapamycin on nanoparticles, which is called FIRN. FIRN show good efficacy, stability, and inflammatory joint targeting ability in an RA mouse model. The findings clarify how fibroblast phenotypes are modulated in the inflammatory microenvironment and provide insights into novel therapeutic designs for autoimmune diseases based on regulatory fibroblasts.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulatory Fibroblast‐Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…TAMs can promote tumorigenesis, progression, metastasis, and drug resistance by inducing angiogenesis, lymph angiogenesis, promoting cancer stem cells, promoting tumor cell proliferation, promoting tumor cell migration, inducing epithelium-mesenchymal transition, inducing matrix degeneration, and inducing immunosuppression [4]. In addition, cancer cells can weaken the phagocytosis of TAMs by CD47 signaling [169,170]. Targeting TAMs, including induction of M1 polarization, reduction of infiltration, and inhibition of M2 polarization, has promising results in murine models and preliminary clinical trials.…”

Section: Multiple Roles Of Tams In Solid Tumorsmentioning

confidence: 99%

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Liu

Zheng

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The failure of CAR-T and immune checkpoint blockade in several solid neoplasms is attributed to multiple factors, including low antigenicity of tumor cells, low infiltration of effector T cells, and diverse mechanisms of immunosuppression in the tumor microenvironment. New adoptive cell therapies have been attempted for solid neoplasms, including TCR-T, CAR-natural killer cells (CAR-NK), and CAR-macrophages (CAR-M). Compared to CAR-T, these new adoptive cell therapies have certain advantages in treating solid neoplasms. In this review, we summarized the 40-year evolution of adoptive cell therapies, then focused on the advances of TCR-T, CAR-NK, and CAR-M in solid neoplasms and discussed their potential clinical applications.

show abstract

“…For example, ALIX, TSG101, and syntenin-1 are implicated in the biogenesis of exosomes and endosomal trafficking [ 55 , 56 ]. CD47 can protect cells and sEVs from phagocytosis, suggesting the possible mechanism by which sEVs escape phagocytic clearance [ 57 ]. ITGB1 can work synergistically with other proteins in cellular targeting and the internalization of exosomes [ 58 ].…”

Section: Extracellular Vesiclesmentioning

confidence: 99%

Extracellular Vesicles for Dental Pulp and Periodontal Regeneration

Lai

Kou

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are lipid bound particles derived from their original cells, which play critical roles in intercellular communication through their cargoes, including protein, lipids, and nucleic acids. According to their biogenesis and release pathway, EVs can be divided into three categories: apoptotic vesicles (ApoVs), microvesicles (MVs), and small EVs (sEVs). Recently, the role of EVs in oral disease has received close attention. In this review, the main characteristics of EVs are described, including their classification, biogenesis, biomarkers, and components. Moreover, the therapeutic mechanism of EVs in tissue regeneration is discussed. We further summarize the current status of EVs in pulp/periodontal tissue regeneration and discuss the potential mechanisms. The therapeutic potential of EVs in pulp and periodontal regeneration might involve the promotion of tissue regeneration and immunomodulatory capabilities. Furthermore, we highlight the current challenges in the translational use of EVs. This review would provide valuable insights into the potential therapeutic strategies of EVs in dental pulp and periodontal regeneration.

show abstract

CD47 as a promising therapeutic target in oncology

Cited by 28 publications

References 146 publications

Regulatory Fibroblast‐Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis

Regulatory Fibroblast‐Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Extracellular Vesicles for Dental Pulp and Periodontal Regeneration

Contact Info

Product

Resources

About